DFJ Growth, a venture capital firm, led a $225m Series B funding round in Delfi Diagnostics, a developer of a blood test system designed for early detection of cancer, with participation from Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, T. Rowe Price, Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, and Windham Venture Partners. "Cancer is a global public health problem and addressing it requires a solution that is accessible around the world. We believe our approach is uniquely capable of delivering high performing, cost effective, and clinically relevant tests for multiple applications to meet the needs of patients and providers everywhere," Victor Velculescu, Delfi CEO and Founder.